Clinical Trial Update: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Inclisiran to prevent cardiovascular events in high-risk individuals for primary prevention of atherosclerotic cardiovascular …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• Inclisiran (inclisiran)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Prevention of Atherosclerotic Cardiovascular Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING